GUARNERI, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.556
AS - Asia 1.822
EU - Europa 1.774
SA - Sud America 13
OC - Oceania 8
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 18.180
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.527
SG - Singapore 771
CN - Cina 758
IT - Italia 702
FI - Finlandia 319
SE - Svezia 236
FR - Francia 178
GB - Regno Unito 134
IN - India 106
VN - Vietnam 103
DE - Germania 92
HK - Hong Kong 40
IE - Irlanda 31
CA - Canada 29
NL - Olanda 21
BR - Brasile 10
CZ - Repubblica Ceca 10
ES - Italia 10
UA - Ucraina 10
BE - Belgio 9
PH - Filippine 8
MK - Macedonia 7
CH - Svizzera 5
KR - Corea 5
TR - Turchia 5
AU - Australia 4
EG - Egitto 4
JP - Giappone 4
NZ - Nuova Zelanda 4
ID - Indonesia 3
IL - Israele 3
IR - Iran 3
NP - Nepal 2
SI - Slovenia 2
TW - Taiwan 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AT - Austria 1
BD - Bangladesh 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
EU - Europa 1
HR - Croazia 1
KZ - Kazakistan 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
PT - Portogallo 1
RS - Serbia 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 18.180
Salva come PNG Salva come JPEG
Città #
Fairfield 2.653
Woodbridge 1.464
Houston 1.339
Chandler 1.098
Ashburn 1.097
Ann Arbor 979
Cambridge 884
Seattle 884
Wilmington 779
Singapore 614
Boardman 420
San Diego 266
Medford 251
Princeton 251
Padova 240
Des Moines 208
Santa Clara 201
Helsinki 169
Beijing 166
Nanjing 117
Roxbury 109
Dong Ket 102
Pune 70
New York 58
Milan 53
London 46
Shenyang 42
Guangzhou 41
Nanchang 33
Rome 32
Dublin 31
Hebei 29
Jinan 28
Ogden 26
Tianjin 26
Dallas 25
Jiaxing 22
Columbus 19
Hong Kong 19
Changsha 18
Norwalk 18
Ottawa 17
Falls Church 16
Lappeenranta 15
Arezzo 14
Turin 13
Kilburn 11
Venice 11
Bologna 10
Los Angeles 10
Washington 10
Zhengzhou 10
Brussels 9
Codogno 9
Hounslow 9
Kharkiv 9
Naples 9
Selvazzano Dentro 9
Chiswick 8
Olomouc 8
Vicenza 8
Haikou 7
Paris 7
Redwood City 7
Shanghai 7
Stockholm 7
Tappahannock 7
Verona 7
Frankfurt am Main 6
Hefei 6
New Bedfont 6
Pignone 6
Rubano 6
Amsterdam 5
Council Bluffs 5
Florence 5
Mumbai 5
Munich 5
Ningbo 5
Piove Di Sacco 5
Skopje 5
São Paulo 5
Acton 4
Borås 4
Capo d'Orlando 4
Chicago 4
Dronten 4
Enterprise 4
Hangzhou 4
Islington 4
Lanzhou 4
Lucca 4
Modena 4
San Francisco 4
Southwark 4
Springfield 4
Taiyuan 4
Todi 4
Ahmedabad 3
Avezzano 3
Totale 15.336
Salva come PNG Salva come JPEG
Nome #
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 185
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 176
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 147
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 146
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 145
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 141
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 139
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 137
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 133
In response to Jackson letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens 130
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 130
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 129
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 129
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 127
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 126
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 126
Immune characterization of breast cancer metastases: Prognostic implications 124
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 123
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 122
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 121
Escalation and de-escalation in HER2 positive early breast cancer 118
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 117
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 116
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 115
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 114
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: Individual patient data meta-analysis 113
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 112
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 112
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 109
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 106
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 104
Olaparib for the treatment of breast cancer 103
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 102
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? 102
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 102
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 101
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study 100
Fat grafting for breast cancer patients: From basic science to clinical studies 100
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 99
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 98
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 96
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study 95
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 94
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 94
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 94
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 94
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies 93
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 93
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 93
Achievements and unmet needs in the management of advanced ovarian cancer 92
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 92
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 91
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study. 91
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 90
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 89
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 89
Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. 89
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 86
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis 85
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 85
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. 84
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer 84
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 84
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial 83
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 83
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden 83
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents 83
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 83
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. 83
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 81
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 81
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients 80
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 80
Clinical utility of measuring circulating tumor cells in metastatic breast cancer 80
Controversies of chemotherapy for the treatment of metastatic breast cancer. 80
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 80
The curability of breast cancer and the treatment of advanced disease 79
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 79
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma 79
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 79
Biomarkers predicting clinical benefit: fact or fiction? 78
Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas 78
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 78
HER2-Positive Early Breast Cancer 78
Trastuzumab containing regimens for early breast cancer. 78
The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View 77
Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients 77
Timing for starting second line therapy in recurrent ovarian cancer. 77
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study 76
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. 76
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 76
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) 75
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 75
PIK3CA: a Target or a Marker in Breast Cancers 75
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 74
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 74
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. 74
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 74
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 74
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy 74
Totale 9.850
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.017
article - articoli 82.179
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.208
Totale 167.404
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.119 0 0 0 0 325 192 287 330 396 293 183 113
2020/20212.994 93 162 91 143 135 549 296 196 372 368 271 318
2021/20223.568 155 396 432 199 306 246 284 273 215 116 263 683
2022/20232.371 483 225 109 279 319 248 48 148 325 35 118 34
2023/20241.683 100 194 161 121 103 237 129 90 92 79 178 199
2024/20251.887 25 529 312 250 771 0 0 0 0 0 0 0
Totale 18.563